Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study
Daniele Campa, Myrto Barrdahl, Aurelia Santoro, Gianluca Severi, Laura Baglietto, Hanane Omichessan, Rosario Tumino, H Bas Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass, Maria-Dolores Chirlaque, Miguel Rodriguez-Barranco, Antonio Agudo, Marc Gunter, Laure Dossus, Vittorio Krogh, Giuseppe Matullo, Antonia Trichopoulou, Ruth C Travis, Federico Canzian Show all
Breast Cancer Research | BIOMED CENTRAL LTD | Published : 2018
Awarded by Health Research Fund (FIS)
Awarded by Instituto de Salud Carlos III (ISCIII) Redes tematicas de investigacion cooperativa en salud (RETICS) (Spain)
Awarded by Cancer Research UK
Awarded by Medical Research Council (United Kingdom)
The coordination of the EPIC study is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the following organizations: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) (PI13/00061 to Granada, PI13/01162 to EPIC-Murcia), the regional Governments of Andalucia, Asturias, Basque Country, Murcia, and Navarra, and Instituto de Salud Carlos III (ISCIII) Redes tematicas de investigacion cooperativa en salud (RETICS) (RD06/0020) (Spain); and Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford) and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom).